Kumaraguru Action for Relief and Empowerment (KARE), was founded in Nov, 2015 during the Chennai floods. KARE supports the victims of natural disasters such as floods, cyclone and other calamities and has supported during Kerala floods & Gaja Cyclone. This is a volunteer movement of Kumaraguru Institutions where many join hands when the need arises.

KARE COVID 19 Response Bulletin is an effort by a group of Kumaraguru alumni, students & informed citizens alike to clear the clutter around COVID 19 by providing informative, insightful news, articles & data around the world under various tags such as Research, Technology, Education, Economy & Insights with a short summary for each.

 COVID19 Basic Info & Previous Bulletin Link: tinyurl.com/blog-KARE

The global struggle to find a cure

COVID-19 Vaccine Tracker

So far more than 170 vaccine candidates have been tracked by WHO, Here are a number of vaccines in each phase. | Guardian

Teicoplanin – A medicine for Coronavirus

Decades-old antibiotic, Teicoplanin, has shown potential in treating COVID-19 and can be ten to 20 times more effective than HCQ and other drugs being currently used. Teicoplanin belongs to a class of antibiotics called ‘glycopeptide’, which kills bacteria by preventing them from forming the bacterial protective wall that is needed for them to survive. The drug plays a role as a potent inhibitor of main protease. In India, there are around 15 pharmaceutical companies producing the drug, including Glenmark, Biocon, Cipla, Lupin, Zydus Cadila  and Torrent Pharmaceuticals.| ThePrint

Vaccination trials-Not a solution

The Moderna and AstraZeneca studies will involve about 30,000 participants each; Pfizer’s will have 44,000. Half the participants will receive two doses of vaccines separated by three or four weeks, and the other half will receive saltwater placebo shots. The final determination of efficacy will occur after 150 to 160 participants develop COVID-19. Moderna and Pfizer acknowledge their vaccines appear to induce side effects that are similar to the symptoms of mild COVID-19. However, mild COVID-19 is far more common than severe COVID-19, so most of the efficacy data is likely to pertain to mild disease. But there is no guarantee that reducing the risk of mild COVID-19 will also reduce the risk of moderate or severe COVID-19.|NY Times

The scientist behind Sputnik V vaccine defends ‘wartime’ roll-out

There have been a lot of speculations about the speed and of Russian vaccine trials. Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology which produced the Sputnik V vaccine justifies by saying that the pace of its development was necessary under the “wartime” conditions of a pandemic but no corners were being cut. He also said volunteers would be monitored for 180 days after the last of 40,000 participants was vaccinated and would be effective even with low levels of COVID-19 transmission in the Russian capital.| Hindustantimes

Vials vital for COVID-19 vaccine 

Vials are nothing but tiny bottles with special properties that protect their contents and won’t chemically react with the vaccine solution.Earlier this year, worry spread that a shortage of these small bottles would hamper the distribution of the vaccine. Since then, makers of pharmaceutical vials around the world have announced they are stepping up their production. Glassmakers suggest they’ll be able to supply what the world needs once vaccines get regulatory approval. The US National Institute of Standards and Technology sells borosilicate glass standard reference material. The constituents of borosilicate glass are as follows: 80.8% of Silicon dioxide, 12.56% of Boron oxide, 3.98% of sodium oxide, 2.28 % of Aluminium oxide by mass. It also has smaller amounts of chlorine, as well as oxides of iron, titanium, zirconium, calcium, magnesium, and potassium.|C&EN 

Online Portal for Vaccine updates

The Union Health Minister Mr.Harsha Vardhan launched the two online portals of ICMR on the first day of October. The online portal will be a repository for the information about vaccine development in India and even globally. But at the first stage the portal will hold information only about the COVID-19 vaccines and in future it will include the information about vaccines of other diseases also. This portal emerged to create transparency about vaccines so that public will not panic to rumours.India is currently on different phases of clinical trials of three COVID-19 vaccines.The phase-III or the last stage of clinical trial of the COVID-19 vaccine ‘Covishield’, being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began on Monday at the state-run Sassoon General Hospital in Pune, Maharashtra on Monday, a senior official said.India’s indigenous vaccine developers Bharat Biotech International Ltd. are at the second-phase human trial stage and Zydus Cadila is in the process to receive approvals for conducting third-phase clinical trials.|Live Mint 

Half a million sharks may be killed to make COVID-19 vaccine

Shark allies, a Californian based shark support group has said that extracting squalene from sharks in order to develop enough doses of COVID-19 might account for the loss of half a million of them. Squalene is a natural oil used as a medical ingredient to increase the effectiveness of a vaccine by creating a strong immune response. The oil is found richly in vulnerable classes of sharks and threatening their population would soon make them endangered. According to the advocacy group, harvesting an endangered species for a medical component is not considered sustainable. Hence to avoid the menace, tests to find a synthetic version of squalene made from fermented sugar cane are underway. |India Today

Pfizer’s COVID-19 antiviral heads for clinical trials

Pfizer has begun Phase 1 clinical tests of PF-07304814, a small molecule that could be used to fight SARS-CoV-2. PF-07304814 contains a phosphate group that makes the compound soluble and gets cleaved by alkaline phosphatase enzymes in tissue, releasing the active antiviral PF-00835231. The 3CL protease of SARS-CoV is very similar to that of SARS-CoV-2, and the two proteases’ active sites are identical, so Pfizer scientists are now working on cellular tests against SARS-CoV-2. PF-07304814 must be given intravenously.|C&EN

COVID-19 vaccine trials : Side-effects reported

Five participants of the COVID-19 vaccination trials reported exhaustion, fever and headaches for a whole day after being administered the vaccine. The candidates, three in Moderna’s study and two in Pfizer’s late-stage trials experienced these symptoms after receiving shots. Reportedly, the Candidates encountered  mild COVID-19 symptoms after phase one trials but experienced intense discomfort such as shakes, chills, headache and shortness of breath for 8 hours after receiving the consequent doses. However, it is said that these symptoms lasted for a whole day or for a few hours in some cases. |India Today

Oxford vaccines trial running smoothly in India

Later phase trials of Oxford AstraZeneca vaccine known as “Covishield” in India are running good with no major adverse side effects.Currently under phase 2 and phase 3, is being administered among large groups. Only very few people developed fevers after the dosage, a mild reaction. Researchers said the vaccine trial will complete in 2 months and then side effects would be monitored . PI says “it’s  safe” , even if only one dose has been administered so far. The race to develop an effective vaccine against COVID-19 has produced over 190 candidates across the world, 41 of which are under clinical evaluation. |ThePrint

‘Antisera’ for virus cure and prevention

The Indian Council of Medical Research (ICMR) said it has developed a highly purified ‘Antisera’ for prevention and treatment of the novel Coronavirus pandemic. Biological E. Limited is one among the listed entities, which have been allowed by the Central Drugs Standard Control Organisation  to manufacture the vaccines for limited use. The top medical body also stated that such measures have previously been used in medical science to control many viral and bacterial infections, including Rabies, Hepatitis B, Vaccinia virus, Tetanus, Botulism and Diphtheria. The efficacy and concentration of antibodies keep varying from one patient to another and therefore make it an unreliable clinical tool for patient management. Meanwhile, India’s recovery rate stands at a whooping height of 83.53% and the fatality rate has come down to 1.56%|Live Mint

October : A critical month for the COVID-19 vaccine

Pfizer Inc. and German partner BioNTech SE this month plan to reveal late-stage results and also could potentially file for FDA approval of its vaccine this month. Moderna Inc., running a close second to Pfizer in the race to a vaccine, is expected to release Phase 2 results this month and data from a 30,000-patient trial as early as November. Novavax Inc. is planning to start enrollment in its own 30,000-person vaccine study in the U.S. in mid-October. The University of Oxford remains on hold, though European regulators plan to review those shots on a rolling basis. Sanofi and partner Translate Bio Inc. are among the companies taking a more measured approach. They may kick off a clinical trial of a messenger-RNA vaccine before the year is out. Sanofi is also pursuing a vaccine with GlaxoSmithKline Plc that uses technology from flu shots that could be in Phase 3 testing in December. The antibody therapies from Regeneron Pharmaceuticals Inc., Merck & Co, Vir Biotechnology Inc, and Eli Lilly & Co could be used in a similar manner for prevention.|Live Mint

Moderna’s COVID-19 vaccine spurs “Strong immune response”

Phase 1 trial has revealed that COVID-19 vaccine developed by Moderna, a US based pharmaceutical  company elicited strong immune response in older adults with no serious side effects. Vaccine called m-RNA-1273, is being developed by Moderna in partnership with the US government’s NIH. Studies say that testing the vaccine on older participants was of “paramount importance”. Participants of study were divided into 2 groups. Group 1 – age between 56 to 70 and Group 2 – age 71 and older, both received dosage of 25 mg or 100 mg of vaccine ,28 days apart. Over 30 other vaccine candidates have entered the clinical trial stage to test for safety.|ThePrint

Where can we get authentic information about Coronavirus?

KARE COVID-19 Response 

KARE is now supporting the front-line workers through local government by providing Food, Personal Protective Equipment (PPE) & sanitizers made in-house at the Kumaraguru Institutions. KARE is also connecting the farmers with communities who would required vegetables in bulk.

KARE COVID-19 Response So Far 

  • 43038 Cooked meals
  • 2259 Volunteering hours clocked
  • 10 Tons of Vegetables transacted so far
  • 28+ Number of Farmers impacted so far
  • 500 kg Rice
  • 1300 Liquid sanitizer packs
  • 2500 Masks
  • ₹ 4,95,141 Funds Raised
  • ₹ 6,50,000 Funds Spent
  • 57000+  Lives Impacted

Impact areas: 

Chinnavedampatti, Saravanampatty, Vellaikinar, Sathyamangalam, Sulthanpet, Paapampatti, Sulur, Thondamuthur, Narasipuram, Kangayam, Coimbatore & Pollachi.


KARE Bank Account Details

Account name: KCT KARE
Account number: 1245155000078376
Bank: Karur Vysya Bank
Branch: KCT Extension Counter
IFSC: KVBL0001245
Bank address: Kumaraguru College of Technology, Chinnavedampatti,Coimbatore – 641036